West Pharmaceutical Services, Inc.
WST
$331.73
-$5.18-1.54%
| Weiss Ratings | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | B- | |||
| Rating Factors | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Weak | |||
| Growth Index | Fair | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.93 | |||
| Price History | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.27% | |||
| 30-Day Total Return | 3.88% | |||
| 60-Day Total Return | 13.99% | |||
| 90-Day Total Return | 9.07% | |||
| Year to Date Total Return | 1.02% | |||
| 1-Year Total Return | -6.47% | |||
| 2-Year Total Return | 32.13% | |||
| 3-Year Total Return | -17.08% | |||
| 5-Year Total Return | 114.12% | |||
| 52-Week High % Change | -19.81% | |||
| 52-Week Low % Change | 25.18% | |||
| Price | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $413.70 | |||
| 52-Week Low Price | $265.00 | |||
| 52-Week Low Price (Date) | Jul 25, 2024 | |||
| 52-Week High Price (Date) | Feb 07, 2024 | |||
| Valuation | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 24.02B | |||
| Enterprise Value | 23.84B | |||
| Price/Earnings (TTM) | 49.28 | |||
| Earnings Per Share (TTM) | 6.73 | |||
| Earnings Per Share Growth | -9.22% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 8.47 | |||
| Price/Book (Q) | 8.74 | |||
| Enterprise Value/Revenue (TTM) | 8.29 | |||
| Price | $331.73 | |||
| Enterprise Value/EBITDA (TTM) | 31.99 | |||
| Enterprise Value/EBIT | 40.08 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 73.40M | |||
| Dividend Yield | 0.24% | |||
| Div. Per Share (Most Recent) | $0.21 | |||
| Dividend Per Share (TTM) | $0.81 | |||
| Payout Ratio (TTM) | 11.73% | |||
| Dividend Per Share (Most Recent) | $0.21 | |||
| Company Info | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 610 594 2900 | |||
| Address | 530 Herman O. West Drive Exton, PA 19341-1147 | |||
| Website | www.westpharma.com | |||
| Country | United States | |||
| Year Founded | 1923 | |||
| Profitability | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 20.67% | |||
| Profit Margin | 17.36% | |||
| Management Effectiveness | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 10.01% | |||
| Return on Equity | 17.78% | |||
| Income Statement | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.88B | |||
| Total Revenue (TTM) | 2.88B | |||
| Revenue Per Share | $39.19 | |||
| Gross Profit (TTM) | 1.00B | |||
| EBITDA (TTM) | 745.40M | |||
| EBIT (TTM) | 594.80M | |||
| Net Income (TTM) | 499.60M | |||
| Net Income Avl. to Common (TTM) | 499.60M | |||
| Total Revenue Growth (Q YOY) | -0.07% | |||
| Earnings Growth (Q YOY) | -15.69% | |||
| EPS Diluted (TTM) | 6.73 | |||
| EPS Diluted Growth (Q YOY) | -13.55% | |||
| Balance Sheet | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 490.90M | |||
| Cash Per Share (Q) | $6.69 | |||
| Total Current Assets (Q) | 1.55B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 2.75B | |||
| Current Ratio (Q) | 3.002 | |||
| Book Value Per Share (Q) | $37.96 | |||
| Total Assets (Q) | 3.68B | |||
| Total Current Liabilities (Q) | 516.50M | |||
| Total Debt (Q) | 307.90M | |||
| Total Liabilities (Q) | 923.00M | |||
| Total Common Equity (Q) | 2.75B | |||
| Cash Flow | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -382.70M | |||
| Cash from Financing (TTM) | -743.20M | |||
| Net Change in Cash (TTM) | -407.70M | |||
| Levered Free Cash Flow (TTM) | 202.13M | |||
| Cash from Operations (TTM) | 702.40M | |||
